Humasis Co

Humasis Co Current Assets

The Current Assets of Humasis Co (205470.KQ) as of Nov 9, 2026 is 5.22 B KRW. In the previous year, Current Assets was 209.92 B KRW — a change of -97.52% (lower).

Current Assets

5.22 BKRW

YoY

-97.52%

Last updated:

Current Assets of Humasis Co is 2025 5.22 B KRW. Current Assets of Humasis Co was 2024 209.92 B KRW. It decreases by -97.52% lower compared to the previous year.

The Humasis Co Current Assets history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Current Assets
Date
Current Assets
Jan 1, 2018
26.00 B KRW
Jan 1, 2019
25.82 B KRW
Jan 1, 2020
44.37 B KRW
Jan 1, 2021
286.64 B KRW
Jan 1, 2022
370.97 B KRW
Jan 1, 2023
275.06 B KRW
Jan 1, 2024
209.92 B KRW
Jan 1, 2025
5.22 B KRW
The Humasis Co Current Assets history
YEARCurrent AssetsYoY
5.22 BKRW-97.52%
209.92 BKRW-23.68%
275.06 BKRW-25.85%
370.97 BKRW+29.42%
286.64 BKRW+546.09%
44.37 BKRW+71.81%
25.82 BKRW-0.70%
26.00 BKRW+26.84%
20.50 BKRW+69.08%
12.13 BKRW+33,582.75%
36.00 MKRW+63.64%
22.00 MKRW—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Humasis Co Stock analysis

What does Humasis Co do? Humasis Co., Ltd. develops rapid test kits and point-of-care testing instruments for the domestic and overseas markets. The company manufactures immunoquantitative analysis devices, myocardial infarction test equipment, infectious disease detection devices, hormone test devices, and cancer marker test devices. It also researches and develops biomaterials. Humasis sells its products to customers in South Korea and international markets, focusing on healthcare providers and medical institutions that require diagnostic tools for diseases like heart attacks, infections, and cancer. The company's revenue comes from the sale of its diagnostic devices and biomaterials research. Products include immunoquantitative analysis devices, myocardial infarction test equipment, and cancer marker test devices. These are sold to healthcare providers and medical institutions in South Korea and overseas. Humasis targets segments in the medical diagnostics field, particularly for cardiovascular, infectious disease, and oncology applications. Humasis Co., Ltd. operates in the medical device sector, focusing on point-of-care testing solutions. Its product portfolio includes devices for myocardial infarction, infectious diseases, hormones, and cancer markers. The company's sales are driven by demand from hospitals and clinics that need rapid diagnostic tools for patient care. The firm's research and development in biomaterials supports its product offerings in the medical diagnostics market. Humasis Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Humasis Co stock

Current Assets of Humasis Co is 5.22 B KRW in 2025.

Current Assets of Humasis Co changed from 209.92 B KRW to 5.22 B KRW, representing a -97.52% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Current Assets Humasis Co since 2006 – with annual values, charts, and detailed analysis.

Current assets are assets expected to be converted to cash within one year, including cash, receivables, and inventory.

Current Assets's KRW is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Current Assets's Humasis Co historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — Humasis Co

All Key Metrics — Humasis Co